BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.

Hitomi MoriMakoto KuboReiki NishimuraTomofumi OsakoNobuyuki ArimaYasuhiro OkumuraMasayuki OkidoMai YamadaMasaya KaiJunji KishimotoTetsuyuki MiyazakiYoshinao OdaTakao OtsukaMasafumi Nakamura

Published in: PloS one (2016)

The 66.4% patients of TNBCs showed BRCAness. BRCAness is essential as a biomarker in the subclassification of TNBCs and might be of use for predicting their prognosis. Furthermore, this biomarker might be a predictive factor for the effectiveness of anthracycline-based adjuvant chemotherapy for patients with TNBCs.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
randomized controlled trial
systematic review
prognostic factors
peritoneal dialysis
patient reported outcomes